



**YiChang HEC ChangJiang Pharmaceutical Co., Ltd.**  
**宜昌東陽光長江藥業股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 01558)**

**Supplemental Form of Proxy for the Annual General Meeting to be held on Friday, 2 June 2023  
(or any adjournment thereof)**

<b>Number of Shares Related to this Supplemental Form of Proxy</b> <i>(Note 1)</i>	<b>Domestic Shares</b>
	<b>H Shares</b>

I/We *(Note 2)* \_\_\_\_\_  
of (address) \_\_\_\_\_  
being the registered holder(s) of \_\_\_\_\_ domestic shares/H shares *(Note 3)*  
of RMB1.00 each in the share capital of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the "Company") hereby appoint **the Chairman of the meeting**  
**or** \_\_\_\_\_ *(Note 4)*  
of (address) \_\_\_\_\_  
as my/our proxy to attend and vote for me/us and on my/our behalf at the annual general meeting of the Company (the "AGM") to be held at Conference Room, 4/F, Administration Building, Dongyangguang Scientific Park, No. 368 Zhen An Zhong Road, Chang'an County, Dongguan, Guangdong Province, the People's Republic of China (the "PRC"), at 10:00 a.m. on Friday, 2 June 2023 (or at any adjournment thereof) in respect of the resolutions as set out in the supplemental notice of AGM dated 17 May 2023 as hereunder indicated and, if no such indication is given, as my/our proxy thinks fit.

<b>ORDINARY RESOLUTIONS</b>		<b>For</b> <i>(Note 5)</i>	<b>Against</b> <i>(Note 5)</i>	<b>Abstain</b> <i>(Note 5)</i>
8.	<b>THAT</b> (a) the execution of the Energy Purchase Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Energy Purchase Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Circular be and are hereby approved.			
9.	<b>THAT</b> (a) the execution of the APIs Purchase Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the APIs Purchase Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Circular be and are hereby approved.			
10.	<b>THAT</b> (a) the execution of the Packaging and Production Materials Purchase Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Packaging and Production Materials Purchase Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Circular be and are hereby approved.			
11.	<b>THAT</b> (a) the execution of the Equipment Purchase and Civil Construction Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Equipment Purchase and Civil Construction Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Circular be and are hereby approved.			
12.	<b>THAT</b> (a) the execution of the Entrusted Processing Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Entrusted Processing Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Circular be and are hereby approved.			
13.	<b>THAT</b> (a) the execution of the Equipment Sales Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Equipment Sales Framework Agreement and the proposed annual cap for the year ending 31 December 2023 as set out in the Circular be and are hereby approved.			
14.	<b>THAT</b> (a) the execution of the Entrusted Production and Inspection Services Framework Agreement (as defined in the Circular) by any director(s) of the Company be and is hereby approved, confirmed and ratified; and (b) the transactions contemplated under the Entrusted Production and Inspection Services Framework Agreement and the proposed annual caps for the three years ending 31 December 2023, 2024 and 2025 as set out in the Circular be and are hereby approved.			

Date: \_\_\_\_\_

Signature *(Note 6)*: \_\_\_\_\_

*Notes:*

1. Please insert the number of shares of the Company registered in your name(s) to which this supplemental form of proxy relates. If a number is inserted, this supplemental form of proxy will be deemed to relate only to those shares. If no number is inserted, the supplemental form of proxy will be deemed to relate to all shares of the Company registered in your name(s) (whether alone or jointly with others).
2. Please insert the full name(s) and address(es) as registered in the register of members of the Company in **BLOCK LETTERS**.
3. Please insert the number of shares of the Company registered in your name(s) and delete as appropriate.
4. If any proxy other than the Chairman of the meeting of the Company is preferred, please strike out the words “**the Chairman of the meeting or**” and insert the name of the proxy desired in the space provided. A shareholder may appoint one or more proxies to attend and vote on his/her behalf. A proxy need not be a shareholder of the Company. Any alteration made to this supplemental form of proxy must be initialed by the person who signs it.
5. Important: If you wish to vote for any resolution, please put a tick in the box marked “FOR” or insert the number of shares held by you. If you wish to vote against any resolution, please put a tick in the box marked “AGAINST” or insert the number of shares held by you. If you want to abstain from voting on any resolution, please put a tick in the box marked “ABSTAIN” or insert the number of shares held by you. If no direction is given, your proxy may vote as he/she thinks fit. The shares abstained will be counted in the calculation of the required majority.
6. This supplemental form of proxy must be signed by you or your attorney duly authorized in writing or, in the case of a corporation, must be either executed under its common seal or under the hand of its director or attorney or other officer duly authorized. In case of joint holders, this supplemental form of proxy may be signed by any of such joint holders.
7. To be valid, this supplemental form of proxy and, if such proxy is signed by a person on behalf of the appointer pursuant to a power of attorney or other authority, a notarized copy of that power of attorney or other authority must be delivered, for holders of Domestic Shares, to the Company’s Board office at Securities Department, Dongyanguang Scientific Park, No. 368 Zhen An Zhong Road, Chang’an County, Dongguan, Guangdong Province, the PRC, or for holders of H Shares, to the Company’s H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong not less than 24 hours before the time for holding of the AGM or any adjournment thereof (i.e. before 10:00 a.m. on Thursday, 1 June 2023).
8. Where there are joint holders of any share of the Company, any one of such persons may vote at the AGM, either personally or by proxy, in respect of such share as if he or she was solely entitled thereto, but if more than one of such joint holders are present at the AGM, personally or by proxy, that one of the said persons so present whose name stands first on the register in respect of such share shall alone be entitled to vote in respect thereof. The vote of the senior joint shareholder who tenders a vote, whether in person or by proxy, will be accepted to the exclusion of the votes of the other joint shareholder(s) and for this purpose, seniority will be determined by the order in which the names stand in the register of members of the Company in respect of the joint shareholding of such shares.
9. This supplemental form of proxy is for the purpose of the supplemental resolutions set out in the supplemental notice of the AGM dated 17 May 2023 and only serves as a supplement to the original form of proxy for the AGM.
10. This supplemental form of proxy will not affect the validity of any form of proxy duly completed by you in respect of the resolutions set out in the notice of the AGM dated 24 April 2023. If you have validly appointed a proxy to attend and act for you at the AGM but do not complete and deliver this supplemental form of proxy, your proxy will be entitled to vote at his/her discretion on the resolutions set out in the supplemental notice of the AGM dated 17 May 2023. If you do not duly complete and deliver the original form of proxy but have duly completed and delivered this supplemental form of proxy and validly appointed a proxy to attend and act for you at the AGM, your proxy will be entitled to vote at his/her discretion on the resolutions set out in the notice of the AGM dated 24 April 2023.
11. Please be advised that completion and delivery of this supplemental form of proxy will not preclude you from attending and voting at the AGM or any of its adjournments in person should you so wish.
12. Unless otherwise defined, capitalized terms used in this supplemental form of proxy shall have the same meaning as those defined in the supplemental circular of the Company dated 17 May 2023.